🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with estimates suggesting in excess of 82 million infections annually. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to findings detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The study involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in many developing nations.

Clinicians treating patients have voiced hope. Access to a single-dose, oral treatment like this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to alleviate the strain of the illness for individuals and to stop the proliferation of untreatable gonorrhoea globally.